Pomalidomide: Phase II data

A Phase II trial in 70 patients with MM refractory to both Revlimid lenalidomide and Velcade bortezomib showed that

Read the full 198 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE